Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
XOMA Corporation is a biotechnology business based in the US. XOMA Corporation shares (XOMA) are listed on the NASDAQ and all prices are listed in US Dollars. XOMA Corporation employs 11 staff and has a trailing 12-month revenue of around USD$2.2 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$45.56 |
---|---|
52-week range | USD$14.14 - USD$46.32 |
50-day moving average | USD$36.4388 |
200-day moving average | USD$24.1213 |
Wall St. target price | USD$33 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-0.984 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $45.56 from 2020-12-18
1 week (2021-01-09) | N/A |
---|---|
1 month (2020-12-16) | N/A |
3 months (2020-10-16) | N/A |
6 months (2020-07-16) | N/A |
1 year (2020-01-16) | N/A |
---|---|
2 years (2019-01-16) | N/A |
3 years (2018-01-16) | N/A |
5 years (2016-01-16) | N/A |
Revenue TTM | USD$2.2 million |
---|---|
Gross profit TTM | USD$17.1 million |
Return on assets TTM | -10.59% |
Return on equity TTM | -42.89% |
Profit margin | 0% |
Book value | $3.451 |
Market capitalisation | USD$482 million |
TTM: trailing 12 months
There are currently 441,755 XOMA Corporation shares held short by investors – that's known as XOMA Corporation's "short interest". This figure is 21% down from 558,844 last month.
There are a few different ways that this level of interest in shorting XOMA Corporation shares can be evaluated.
XOMA Corporation's "short interest ratio" (SIR) is the quantity of XOMA Corporation shares currently shorted divided by the average quantity of XOMA Corporation shares traded daily (recently around 43098.048780488). XOMA Corporation's SIR currently stands at 10.25. In other words for every 100,000 XOMA Corporation shares traded daily on the market, roughly 10250 shares are currently held short.
However XOMA Corporation's short interest can also be evaluated against the total number of XOMA Corporation shares, or, against the total number of tradable XOMA Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case XOMA Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 XOMA Corporation shares in existence, roughly 40 shares are currently held short) or 0.054% of the tradable shares (for every 100,000 tradable XOMA Corporation shares, roughly 54 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against XOMA Corporation.
Find out more about how you can short XOMA Corporation stock.
We're not expecting XOMA Corporation to pay a dividend over the next 12 months.
XOMA Corporation's shares were split on a 1:20 basis on 18 October 2016. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your XOMA Corporation shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for XOMA Corporation shares which in turn could have impacted XOMA Corporation's share price.
Over the last 12 months, XOMA Corporation's shares have ranged in value from as little as $14.14 up to $46.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while XOMA Corporation's is 0.9864. This would suggest that XOMA Corporation's shares are less volatile than average (for this exchange).
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.